Are Natural Resource Partners LP(NRP), ImmunoCellular Therapeutics Ltd(IMUC) and Raptor Pharmaceutical Corp.(RPTP) Taking A Temporary Hit?

Posted by Saimoon February 16, 2015 0 Comment 1244 views


New York, NY – GDP INSIDER  –  02/16/2015.

This article discusses 3 companies Natural Resource Partners LP(NYSE:NRP), ImmunoCellular Therapeutics Ltd(NYSEMKTS:IMUC) and Raptor Pharmaceutical Corp(NASDAQ:RPTP).

Natural Resource Partners LP(NYSE:NRP) released lower than expected earnings on Thursday prompting a downward trend in the stock value on Friday. The mining property leasing and management company has been hit by the fall commodities and reported its quarterly earning down 42.9% year on year as operational costs have increased. A lot of related companies are focusing on reducing their costs as coal, gas and oil prices look unlikely to rise in the near term. The stock dropped 5.42% to $7.86 by close on Friday and may continue to struggle until commodity prices increase.

Should You Invest In Natural Resource Partners LP? See If There Is An End To The Slippery Slope With Our Free NRP Analysis

ImmunoCellular Therapeutics Ltd(NYSEMKTS:IMUC) stock dropped 5.26% on Friday after it announced that it was publicly offering 26.65 million shares of common stock at $0.60 per share. This will give ImmunoCellular a cash influx of over $14 million to complete enrollment of its phase 3 clinical trial of ICT-107 as well funds to increase working capital and other finance other projects. The biotechnology company is working on drugs to combat brain and other types of cancer and if the trials are successful, could be a good long term investment prospect.

Is ImmunoCellular Therapeutics Ltd  A Buy-Low Option? Find Out What Lies Ahead For ImmunoCellular And Where The Profits Are With Free IMUC Analysis.

Raptor Pharmaceutical Corp.(NASDAQ:RPTP) develops advanced drugs for debilitating diseases and currently has several promising new ones under development. The stock has been steadily declining from a high of $10.81 at the start of the year and closed down $4.23% at $9.05 on Friday. The stock has a strong 1 year target estimate of $19.81 which it could meet or exceed if the data from Phase 2b study of its new drug RP103 is a success and sales of its flagship drug Procysbi exceed sales estimates of $70 million in 2015.

Is Raptor Pharmaceutical Corp A Smart Investment Option?Our Free RPTP Analysis Will Help You Decide If Raptor Is A Placebo Or A Financial Pick-Me-Up.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment